Physician profile
Robin Lenz
NPI 1558706218
$7,867.69
in general payments reported to CMS, 2019-2025
32 companies · $2,308 in 2025
The $2,308 reported for 2025 was more than what 86% of Foot & Ankle Surgery providers received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $601 · 2020: $259 · 2021: $1,407 · 2022: $1,360 · 2023: $799 · 2024: $1,133 · 2025: $2,308.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,680 · Travel and Lodging: $560.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,679.99 |
| Travel and Lodging | $560.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $1,985.92 | 2019-2025 | Puraply, Via Matrix, Puraforce |
| Convatec INC. | $1,379.68 | 2024-2025 | |
| Treace Medical Concepts, INC. | $832.49 | 2021-2022 | |
| Integra Lifesciences Corporation | $612.63 | 2019-2024 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Abbott Laboratories | $505.88 | 2023-2024 | Proclaim, Eterna |
| Smith+Nephew, INC. | $326.52 | 2019-2025 | Grafix Pl, Pico 7 |
| Tactile Systems Technology INC | $322.53 | 2022-2025 | Flexitouch Plus, Nimbl, Entre Plus |
| Stryker Corporation | $258.60 | 2021-2022 | |
| Musculoskeletal Transplant Foundation INC. | $171.47 | 2019-2022 | |
| Zimmer Biomet Holdings, INC. | $168.20 | 2019-2021 | |
| Medline Industries Lp | $137.87 | 2019 | |
| W. L. Gore & Associates, INC. | $135.94 | 2023 | Gore Viabahn Endoprosthesis With Heparin |
| Advanced Oxygen Therapy INC. | $130.20 | 2024 | Topical Oxygen Chamber For Extremities |
| Kerecis Limited | $124.85 | 2019-2022 | |
| Amgen INC. | $124.09 | 2024 | Krystexxa |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $115.76 | 2025 | Hawkone |
| Koya Medical, INC. | $98.60 | 2025 | Dayspring, Koya Medical |
| Paratek Pharmaceuticals, INC. | $73.23 | 2022-2024 | Nuzyra |
| Biocomposites INC | $50.55 | 2025 | Stimulan |
| Bioventus LLC | $45.07 | 2022 | |
| Sebela Pharmaceuticals INC. | $39.09 | 2019-2020 | |
| Wright Medical Technology, INC. | $34.79 | 2019 | |
| Cashflow Solutions, LLC | $26.77 | 2025 | Lympha Press Optimal Plus(US) Bt, Pcd-51 731a (US) - White, Pcd-52 737a (US) White |
| Heron Therapeutics, INC. | $25.45 | 2021 | |
| Averitas Pharma INC. | $25.07 | 2024 | Qutenza |
| Acera Surgical, INC. | $23.12 | 2022 | |
| Hartmann USA, INC. | $19.62 | 2025 | Colactive Plus 2x2 |
| Linvatec Corporation | $16.90 | 2023 | Biobrace 23mm |
| Pfizer INC. | $15.71 | 2021 | |
| Melinta Therapeutics, LLC | $14.71 | 2019 | |
| Merck Sharp & Dohme LLC | $14.18 | 2019 | |
| Nabriva Therapeutics, Plc | $12.20 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Lenz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.